Glycogen Synthase Kinase-3β Is Associated with the Prognosis of Hepatocellular Carcinoma and May Mediate the Influence of Type 2 Diabetes Mellitus on Hepatocellular Carcinoma

Guoliang Qiao1*, Yuan Le2*, Jun Li3, Lianghuan Wang2, Feng Shen1*

1 Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China, 2Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai, China

Abstract

Background: Although many studies have shown glycogen synthase kinase-3β (GSK-3β) was associated with type 2 diabetes mellitus (T2DM) and implicated with a wide range of cancers, the role of GSK-3β in hepatocellular carcinoma (HCC) and the correlation among GSK-3β, T2DM and HCC remains unclear. Our objectives were to identify the effect of p-Ser9-GSK-3β on the prognosis of patients with HCC and to learn more about the interaction among T2DM, GSK-3β and the prognosis of HCC.

Methods: Firstly we used reverse transcriptase-PCR (RT-PCR) and western blotting to determine the expression levels of GSK-3β and p-Ser9-GSK-3β in human HCC samples. We then used immunohistochemical staining to evaluate the expression pattern of p-Ser9-GSK-3β in 178 patients with HCC after curative partial hepatectomy. Finally we statistically analyzed the association of p-Ser9-GSK-3β and T2DM with the prognosis of patients with HCC.

Results: P-Ser9-GSK-3β was over-expressed in tumor tissues compared with their normal counterparts. Correlation and regression analysis indicated that the over-expression of p-Ser9-GSK-3β was significantly associated with T2DM, and the correlation coefficient was 0.259 ($P = 0.001$). Multivariate analysis showed that the over-expression of p-Ser9-GSK-3β and T2DM were independently associated with poor prognosis of HCC, respectively. Further analysis demonstrated that these two variables are closely related with each other.

Conclusion: The over-expression of p-Ser9-GSK-3β and T2DM are strongly correlated with worse surgical outcome of HCC. P-Ser9-GSK-3β may play a significant role in mediating the influence of T2DM on the prognosis of HCC.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most frequent cause of cancer-related mortality [1]. Partial hepatectomy remains the standard curative treatment, with a 5-year survival rate of 50%–70% for early HCC [2,3]. Accurately identifying the prognostic factors is important to facilitate screening of high risk patients and make decisions on the adjuvant therapy.

Glycogen synthase kinase 3 (GSK3), a constitutive multi-functional serine threonine kinase, was involved in diversely physiological pathways ranging from insulin signaling pathways which associated with the disease of type 2 diabetes mellitus (T2DM) and Wnt signaling pathways which related to oncogenesis [4–7]. GSK-3β (47 kDa), an isoform of GSK-3, could be inactivated by insulin through phosphorylation of an N-terminal domain serine residue (Ser9 of GSK-3β) [8]. Phosphorylation of Ser9-GSK-3β (p-Ser9-GSK-3β) was associated with the activation of Wnt signaling which could prevent phosphorylation and lead to the stabilization of β-catenin. This mechanism had been reported in a wide range of cancers [9]. However, few researchers reported the significance of GSK-3β or p-Ser9-GSK-3β in the prognostic evaluation of patients with HCC [10].

Currently, epidemiology studies revealed that diabetes mellitus (DM) increased the incidence of HCC [11,12]. Although it remained controversial about the influence of DM on the prognosis of patients with HCC after partial hepatectomy [13,14], accumulating evidence showed that DM was an
Table 1. Correlation between p-Ser9-GSK-3β expression and clinicopathologic features.

| Variables                        | p-Ser9-GSK-3β expression |       |       |      |
|---------------------------------|--------------------------|-------|-------|------|
|                                 | Low (n = 89)             | High (n = 89) | P   |
| Sex                             | female                   | 12    | 14    | 0.671 |
|                                 | male                     | 77    | 75    |       |
| Age                             | median                   | 50    | 49    | 0.613 |
|                                 | range                    | 15–72 | 32–74 |       |
| AFP level (µg/L)                | ≤400                     | 53    | 54    | 0.878 |
|                                 | >400                     | 36    | 35    |       |
| HBsAg                           | positive                 | 79    | 78    | 0.816 |
|                                 | negative                 | 10    | 11    |       |
| HBeAg                           | positive                 | 20    | 13    | 0.177 |
|                                 | negative                 | 69    | 76    |       |
| Liver cirrhosis                 | yes                      | 69    | 75    | 0.253 |
|                                 | no                       | 20    | 14    |       |
| Edmondson-Steiner grade         | I-II                     | 17    | 20    | 0.579 |
|                                 | III-IV                   | 72    | 69    |       |
| Diameter(cm)                    | ≤5                       | 52    | 51    | 0.879 |
|                                 | >5                       | 37    | 38    |       |
| Encapsulation                   | complete                 | 32    | 21    | 0.071 |
|                                 | no                       | 57    | 68    |       |
| MVI                             | yes                      | 29    | 34    | 0.433 |
|                                 | no                       | 60    | 55    |       |
| Tumor number                    | single                   | 76    | 70    | 0.242 |
|                                 | multiple                 | 13    | 19    |       |
| TBL (µmol/l)                    | median                   | 15.4  | 16    | 0.603 |
|                                 | range                    | 4.2–56.7 | 4.6–64.4 |       |
| Alb (g/dl)                      | median                   | 38.4  | 40    | 0.092 |
|                                 | range                    | 24.5–51.4 | 23.6–53.8 |       |
| ALT (U/L)                       | median                   | 54.9  | 55.5  | 0.887 |
|                                 | range                    | 10.6–235.7 | 8.3–240.3 |       |
| WBC                             | median                   | 5.2   | 5.1   | 0.611 |
|                                 | range                    | 2.5–13.7 | 3.1–14.8 |       |
| RBC                             | median                   | 4.4   | 4.3   | 0.348 |
|                                 | range                    | 3.2–5.8 | 2.8–5.4 |       |
| PLT (×10^9/L)                   | median                   | 124   | 122   | 0.783 |
|                                 | range                    | 22–359 | 17–367 |       |
| INR                             | median                   | 1.05  | 1.04  | 0.308 |
|                                 | range                    | 0.87–1.26 | 0.89–1.23 |       |
| CR                              | median                   | 70    | 68    | 0.454 |
|                                 | range                    | 40–136 | 38–139 |       |
| MELD score                      | median                   | 7.6   | 7.5   | 0.564 |
|                                 | range                    | 6.0–12 | 6.0–11 |       |
| T2DM                            | yes                      | 6     | 23    | 0.001 |
|                                 | no                       | 83    | 66    |       |

Abbreviations: AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; HBeAg, Hepatitis E antigen; MVI, microvascular invasion; TBL, total bilirubin; ALB, albumin; ALT, alanine; WBC, white blood cell; RBC, red blood cell; PLT, platelet count; INR, international normalized ratio; CR, creatinine; MELD, model for end-stage liver disease; T2DM, type 2 diabetes mellitus.
doi:10.1371/journal.pone.0105624.t001

independent prognostic indicator for patients with HCC after curative resection [15,16]. The purpose of the present study is to identify if the expression level of p-Ser9-GSK-3β is an effective prognostic factor for HCC patients and learn more about the interaction among the T2DM, expression of p-Ser9-GSK-3β and the prognosis of HCC.
Materials and Methods

1. Patients and human HCC specimen

A total of 238 patients with HCC undergoing partial hepatectomy by two independent surgical teams at Eastern Hepatobiliary Surgery Hospital from July 1st, 2003 to May 15th, 2005 were enrolled in this study. The preoperative clinical diagnosis of HCC met the diagnostic criteria of the American Association for the Study of Liver Diseases (AASLD) [17]. Of these surgical HCC specimens, 60 samples which were collected between July 1st and December 15th, 2003, were subjected to RNA and protein extraction that could be done for RT-PCR and western blot analysis. 178 patients collected between December 16th, 2003 and May 15th, 2005 met the following inclusion criteria and then underwent immunohistochemical staining (IHC) and prognostic analyses: had WHO performance status 0-1; did not receive any preoperative anti-cancer therapy; did not have any distant metastasis, image visible ascites, or severe esophageal varices; had the preoperative Child-Pugh class A; received curative hepatectomy; had pathologically proven hepatocellular carcinoma. Patients were excluded from this study if they had a history of other solid tumors, or died from severe postoperative complications. The clinical characteristics of the 178 patients were listed in Table 1.

The definition of curative hepatectomy was described as our previous reports [18]. The histological grade of tumor differentiation was assigned by the Edmondson Steiner grading system [19]. This study was approved by the Institutional Review Board of Eastern Hepatobiliary Surgery Hospital. All patients gave written informed consent to participate. The ethics committees approved this consent procedure. The data did not contain any information that could identify the patients.

2. Immunohistochemistry and evaluation of immunostaining

Immunohistochemical staining was performed with the Dako Envision Plus System (Dako, Carpinteria, CA) according to the manufacturer’s instructions. The primary antibodies were anti-GSK-3β and anti-p-Ser9-GSK-3β (Cell Signaling Technology Inc., Beverly, MA, 1:50). The sections were evaluated as positive for GSK-3β and p-Ser9-GSK-3β staining when there were more than 10% of tumor cells demonstrating cytoplasmic and/or nucleus immunoreaction deposits. The sections were scored with a four-tier scale: 0 = negative (0–10%), 1 = weak signal (10–20%), 2 = intermediate signal (20–50%) and 3 = strong signal (> 50%). 0 and 1 were defined as low expression, while 2 and 3 were defined as over-expression. All sections were scored independently by two observers who did not have any prior knowledge of the clinic-pathologic data. The concordance between scores from different sections of the same tumor was greater than 90%. All discrepancies in scoring were reviewed and a consensus was reached.

3. Western blotting analysis

Fresh surgical specimens were snap frozen in liquid nitrogen and stored in deep freezer. The normal and the tumor tissues were lysed in T-PER Tissue Protein Extraction Reagent (Pierce, Rockford, IL) containing proteinase inhibitors (CalBiochem, San Diego, CA). The extracts were collected and centrifuged at 12,000 x g for 5 min. The protein concentrations were determined using the BCA Protein Assay (Pierce) according to the manufacturer’s instructions. The following antibodies were used: anti-GSK-3β and anti-p-Ser9-GSK-3β (Cell Signaling Technology Inc., Beverly, MA), we also used β-actin as a loading control.

4. RNA extraction and real-time reverse transcriptase-PCR

Total RNA of tissue samples were isolated using TRIzol (Life Technologies, Inc., Rockville, MD) according to the manufacturer’s instructions. cDNA was generated from 1 ug of each RNA sample and a reverse transcribed using a transcription kit (Takara, Kyoto, Japan). Real-time quantitative reverse transcriptase-PCR (RT-PCR) was done in the 7300 Real Time PCR System (Applied Biosystems) to detect GSK-3β gene expression in paired liver samples from 30 HCC patients. The primers were as follows:

Figure 1. Expression of GSK-3β and p-Ser9-GSK-3β in HCC. (A) Relative expression level of GSK-3β mRNA in 60 tumor tissues (TT) and paired non-tumorous tissues (NTT) by RT-PCR (P < 0.001). (B) RT-PCR analysis of GSK-3β mRNA expression. (C) Expressions of p-Ser9-GSK-3β were analyzed by Western Blotting in HCC tumor tissues (TT) and paired non-tumorous tissues (NTT).

doi:10.1371/journal.pone.0105624.g001
GSK-3β, T2DM and the Prognosis of HCC
Figure 2. Immunohistochemical analysis of p-Ser9-GSK-3β expressions in HCCs and the adjacent nontumorous liver tissues. (A-D) Immunohistochemical staining of a paired HCC and nontumoral tissue. HCC cells were strongly positive for p-Ser9-GSK-3β expression in the cytoplasm (A,C). Normal hepatocytes in the nontumoral tissue showed no detectable p-Ser9-GSK-3β expression (B,D). (E-H) Immunohistochemical staining of another paired HCC and nontumoral tissue. HCC cells were strongly positive for p-Ser9-GSK-3β expression in the cytoplasm (E,G). Normal hepatocytes in the nontumoral tissue showed no detectable p-Ser9-GSK-3β expression (F,H). Original magnifications: magnification*50 (C,D,G,H). doi:10.1371/journal.pone.0105624.g002

GSK-3β, forward: 5′-AACACAAACAAGGAGCAA-3′; reverse: 5′-GAGCGTGAGGAGGGATAAGG-3′, 326bp. β-actin, forward: 5′-ACCATGGATGATGATATCGC-3′ and reverse: 5′-ACATGCTGGGGTGTTGAAG-3′, 386bp. β-actin served as an endogenous control. The expression of the target messenger RNA (mRNA) was quantified relative to that of the β-actin mRNA. A ratio of relative GSK-3β mRNA levels in tumor samples/nontumorous samples of 0.5-fold was defined as under-expression of the gene, whereas a ratio of 2.0-fold was defined as over-expression.

5. Diagnosis of Type 2 diabetes

Diagnosis of diabetes mellitus was based on the 1999 World Health Organization criteria. Patients who were found to have a fasting blood sugar level between 5.6 and 6.1 mmol/L were defined as having impaired fasting glucose and were referred for confirmation of their diabetes status. Those with a fasting blood sugar level of at least 7.0 mmol/L or those diagnosed with Type 2 diabetes before entering the hospital were defined as having Type 2 diabetes and were referred for further diabetic care. Patients with prior diagnosis of Type 1 diabetes were excluded from the study.

6. Follow-up

The follow-up ended on May 2012 and the median follow-up duration was 48.2 months (3.8–114.5 months). Contrast-enhanced CT scan or MRI of the abdomen was carried out once every 3 months in the first two years after surgery, and then once every 6 months thereafter. The diagnostic criteria for HCC recurrence was the same as used for the initial diagnosis.

Figure 3. Kaplan-Meier analysis of TTR and OS of patients with HCC. (A,B) Kaplan-Meier curves of the correlation between p-Ser9-GSK-3β expression level and (A) recurrence or (B) overall survival of HCC patients; (C,D) Kaplan-Meier curves of the correlation between T2DM and (A) recurrence or (B) overall survival of HCC patients. doi:10.1371/journal.pone.0105624.g003
7. Statistical analysis

Overall Survival (OS) and Time To Recurrence (TTR) were used as primary endpoints. OS was defined as the interval between hepatectomy and death or the date of last follow-up. TTR was calculated from surgery to the date when recurrence was diagnosed. All statistical calculations were carried out using the SPSS 16.0 software. The \( \chi^2 \) test or Fisher’s exact test were used to compare qualitative variables, while continuous variables were compared using Student’s t-test or Mann-Whitney test for variables with an abnormal distribution. Receiver operating characteristic curve analysis was used to determine the optimal cut-offs of continuous variables. Survival curves were calculated by the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used to determine the independent factors for tumor recurrence and patient’s survival based on the variables selected by univariate analysis. Differences were considered statistically significant at \( p < 0.05 \).

Results

1. Over-expression of GSK-3\( \beta \) and p-Ser9-GSK-3\( \beta \) in HCC samples

We firstly assayed and compared GSK-3\( \beta \) mRNA levels in 60 TTs (tumor tissues) and their matched NTTs (nontumorous tissues) by the way of RT-PCR assay (Fig. 1A, B), in which 50 of 60 (83.3%) specimens showed GSK-3\( \beta \) mRNA over-expression in HCC (tumor/nontumorous ratio 2.0). We found increased protein expression level of total GSK-3\( \beta \) and p-Ser9-GSK-3\( \beta \) in 46 of 60 (76.7%) tumor tissues compared with their normal counterparts by western blotting (Fig. 1C). We then performed immunostaining in the 178 paired HCC samples and found that 89 (50.0%) patients were identified as p-Ser9-GSK-3\( \beta \) over-expression (Fig. 2A-H).

2. Association of p-Ser9-GSK-3\( \beta \) expression with T2DM

We examined the association between the expression level of p-Ser9-GSK-3\( \beta \) in the tumor tissues with T2DM and other clinicopathological characteristics of patients (Table 1). Correlation and regression analysis indicated that the over-expression of p-Ser9-GSK-3\( \beta \) was significantly associated with T2DM, and the correlation coefficient was 0.259 (\( P = 0.001 \)).

3. Association of p-Ser9-GSK-3\( \beta \) expression and T2DM with prognosis of HCC patients

Patients with over-expression of p-Ser9-GSK-3\( \beta \) had higher recurrence rates (1-, 3-, and 5-year recurrence rates: 49.4%, 70.0% and 84.7% vs. 24.9%, 43.1%, and 63.9%, \( P < 0.001 \)), and lower overall survival rates (1-, 3-, and 5-year survival rates: 73.6%, 44.8% and 34.9% vs. 88.5%, 72.8% and 61.5%, \( P < 0.001 \)) than those with low expression.

T2DM was negatively correlated with 1-, 3-, and 5-year survival rates (64.6%, 39.7% and 29% for T2DM vs 84.2%, 62.2% and 51.7% for No T2DM; \( P < 0.001 \)). The 1-, 3-, and 5-year cumulative recurrence rates in patients with T2DM were significantly higher than those in patients with No T2DM (58.6%, 78.9% and 91.6% vs 33.1%, 52.4% and 71.2%; \( P < 0.001 \)).

Based on Kaplan-Meier survival analysis, the comparisons of p-Ser9-GSK-3\( \beta \) expression levels (high or low) in the 178 patients with HCC were shown in the Fig 3A, B. The comparisons of patients with no T2DM versus T2DM were shown in the Fig 3C, D.

| Variable | Overall Survival | Overall Survival (exclude T2DM) | Overall Survival (exclude pG) |
|----------|-----------------|---------------------------------|------------------------------|
| HR       | 95% CI          | HR                             | 95% CI                       |
| Tumor Size: Small/Large | 1.42 | 1.156–2.326 | 1.156–2.326 | 1.156–2.326 |
| Microvascular Invasion: Yes/No | 1.63 | 1.082–2.497 | 1.082–2.497 | 1.082–2.497 |
| Tumor Number: Multiple/Solitary | 1.93 | 1.296–3.082 | 1.296–3.082 | 1.296–3.082 |
| p-Ser9-GSK-3\( \beta \) Expression: High/Low | 2.63 | 0.378–0.801 | 0.378–0.801 | 0.378–0.801 |
| T2DM: Yes/No | 1.19 | 0.728–2.010 | 0.728–2.010 | 0.728–2.010 |

Abbreviations: pG, p-Ser9-GSK-3\( \beta \); T2DM, type 2 diabetes mellitus.

Table 2. Multivariate analysis for overall survival.
Univariate analysis of 23 survival-related clinic-pathological variables revealed that serum AFP level (P = 0.024), tumor size (P = 0.003), tumor number (P = 0.022), liver cirrhosis (P = 0.038), microvascular invasion (P = 0.011), p-Ser9-GSK-3β expression level (P < 0.001), and T2DM (P = 0.006) were statistically correlated with OS of patients with HCC (Table S1).

These significant variables were further subjected to multivariate Cox proportional hazards model, which shown that tumor size (P = 0.008), tumor number (P = 0.032), microvascular invasion (P = 0.019), p-Ser9-GSK-3β expression level (P < 0.001), and T2DM (P = 0.006) were independent risk factors that could affect the survival of patients with HCC (Table S1). We speculated that some interaction or colinearity existed between the variables of p-Ser9-GSK-3β and T2DM. Thus, we further conducted multivariate Cox proportional hazards analysis excluding the variables of p-Ser9-GSK-3β or T2DM respectively (Table 2). The results also demonstrated that these two variables were closely related with each other.

4. Stratified analysis of the impact of p-Ser9-GSK-3β expression and T2DM on the prognosis of HCC patients

In the subgroup of tumor size ≤ 5 cm, p-Ser9-GSK-3β over-expressing patients had higher recurrence rates (1-, 3-, and 5-year recurrence rates: 37.3%, 59.9% and 81.6% vs. 15.4%, 29.9%, and 54.6%, P = 0.002), and lower survival rates (1-, 3-, and 5-year survival rates: 82.7%, 52.2%, and 22.0% vs. 96.5%, 71.4%, and 47.3%, P = 0.002). Figure 4. Kaplan-Meier analysis of TTR and OS stratified by tumor diameter of HCC patients. (A,B) Kaplan-Meier curves of the correlation between p-Ser9-GSK-3β expression level, tumor diameter divided by 5 cm and (A) recurrence or (B) overall survival of HCC patients; (C,D) Kaplan-Meier curves of the correlation between T2DM, tumor diameter divided by 5 cm and (C) recurrence or (D) overall survival of HCC patients.

Figure 4. Kaplan-Meier analysis of TTR and OS stratified by tumor diameter of HCC patients. (A,B) Kaplan-Meier curves of the correlation between p-Ser9-GSK-3β expression level, tumor diameter divided by 5 cm and (A) recurrence or (B) overall survival of HCC patients; (C,D) Kaplan-Meier curves of the correlation between T2DM, tumor diameter divided by 5 cm and (C) recurrence or (D) overall survival of HCC patients.
doi:10.1371/journal.pone.0105624.g004

| Groups                        | Survival Comparison (P value) | Recurrent Comparison (P value) | Groups                        | Survival Comparison (P value) | Recurrent Comparison (P value) |
|-------------------------------|-------------------------------|--------------------------------|-------------------------------|-------------------------------|--------------------------------|
| p-Ser9-GSK-3β (Lo) Diameter ≤ 5 cm | No T2DM Diameter ≤ 5 cm     |                                 | 0.028                         | 0.026                         |
| vs. p-Ser9-GSK-3β (Hi) Diameter > 5 cm | No T2DM Diameter > 5 cm     | 0.017                           | vs. No T2DM Diameter > 5 cm   | 0.006                         | 0.01                           |
| vs. p-Ser9-GSK-3β (Lo) Diameter > 5 cm | No T2DM Diameter > 5 cm     | -0.001                          | vs. No T2DM Diameter > 5 cm   | -0.001                        | -0.001                         |
| vs. p-Ser9-GSK-3β (Hi) Diameter > 5 cm | No T2DM Diameter > 5 cm     | 0.397                           | vs. T2DM Diameter > 5 cm      | 0.761                         | 0.77                           |
| vs. p-Ser9-GSK-3β (Lo) Diameter > 5 cm | T2DM Diameter > 5 cm       | 0.022                           | vs. T2DM Diameter > 5 cm      | 0.202                         | 0.171                          |
| vs. p-Ser9-GSK-3β (Hi) Diameter > 5 cm | No T2DM Diameter > 5 cm     | 0.009                           | vs. T2DM Diameter > 5 cm      | 0.125                         | 0.004                          |
survival rates: 82%, 58.1% and 43.9% vs. 94.2%, 83.9% and 72.4%, P<0.001) than those of under-expressing patients.

Similar results were obtained in the tumor size = 5 cm subgroup: the 1-,3-, and 5-year recurrence rates were 65.8%, 83.9% and 87.9% vs. 38.3%, 61.6%, and 77.6% in over-expressing and under-expressing patients, respectively, and the 1-,3-, and 5-year survival rates: 62.5%, 27.2% and 20.4% vs. 80%, 56.3% and 46.2%, respectively (P = 0.056, P = 0.009) (Fig 4A,B).

In the subgroup of tumor size = ≤ 5 cm, patients with T2DM had higher recurrence rates (1-,3-, and 5-year recurrence rates: 47.1%, 73.1% and 86.6% vs. 22.2%, 39.4%, and 65%, P = 0.026), and lower survival rates (1-,3-, and 5-year survival rates: 63%, 54% and 45% vs. 95%, 74.5% and 60.9%, P = 0.028) than those of patients without T2DM.

In the tumor size > 5 cm subgroup: the 1-,3-, and 5-year recurrence rates were 75%, 87.5% and 91.7% vs. 48%, 70.3%, and 79.7% in patients with and without T2DM, respectively, and the 1-,3-, and 5-year survival rates: 66.7%, 19.4% and 9.7% vs. 71.9%, 45.1% and 38.7%, respectively (P = 0.094, P = 0.125) (Fig 4C,D). There were no significant differences in TTR and OS in the subgroup of tumor size > 5 cm, due to the limitation of the amount of patients with T2DM.

We then subdivided HCC patients with T2DM, we found that in the subgroup of without T2DM, p-Ser9-GSK-3β over-expressing patients had higher recurrence rates (1-,3-, and 5-year recurrence rates: 45.5%, 64.8% and 83.3% vs. 23.0%, 42.4%, and 57.1%, P = 0.004), and lower survival rates (1-,3-, and 5-year survival rates: 78.4%, 49.3% and 24.4% vs. 87.6%, 72.4% and 60.7%, P<0.001) than those of under-expressing patients. There were no significant differences in TTR (P = 0.308) and OS (P = 0.057) in the subgroup of with T2DM (Figure S1).

**Discussion**

In the present study, we showed that the total GSK-3β and the p-Ser9-GSK-3β were increased at both mRNA and protein levels in HCC specimens. The over-expression of p-Ser9-GSK-3β was associated with the poor prognosis of patients with HCC after curative resection. We also found that T2DM was related to the poor prognosis of patients with HCC, and the expression level of p-Ser9-GSK-3β was significantly related with T2DM. We speculated that the regulation of GSK-3β might play a significant role in mediating the impact of T2DM on HCC prognosis. To the best of our knowledge, no previous study reported the impact of p-Ser9-GSK-3β expression in the context of HCC and the relationship between the expression of p-Ser9-GSK-3β and T2DM.

GSK-3β was a crucial signaling molecule involved in glycogen synthesis, gene expression, cell migration, cell cycle, cellular architectural pathways and oncogenesis [20,21]. It was a downstream target of insulin and insulin-like growth factor (IGF) receptor-dependent pathways which could result in GSK-3β phosphorylation on the serine 9 residue (p-Ser9-GSK-3β), and subsequent phosphorylation of insulin receptor substrate-1 (IRS1) [22,23]. Insulin receptor substrate (IRS) proteins were major docking proteins that mediated insulin/insulin-like growth factor 1 (IGF1) signaling in various insulin-sensitive tissues [24]. Therefore, dysregulation of GSK-3β could result in attenuating insulin signaling, which was thought to induce insulin resistance. Insulin resistance was a major pathophysiological problem underlying the initiation and progression of type II diabetes mellitus (T2DM) [25]. Moreover, activation of Wnt signaling could lead to GSK-3β inactivation and prevented phosphorylation of β-catenin protein in the cytosol. The increased levels of β-catenin transported to the nuclear, and interacted with transcription factors LEF/TCF (lymphoid enhancer factor/T cell factor) to activate the expression of target genes like c-myc and cyclin D1, and lead to cell proliferation [21,26]. This process was implicated with a wide range of cancers. With respect to HCC, apart from the Wnt-β-catenin pathway, insulin and insulin-like growth factor (IGF) pathways were also implicated with the development and/or progression of HCC [27-29]. GSK-3β was involved in these pathways and recent findings indicated that hyperphosphorylation of Ser9-GSK-3β was a hallmark of hepatocarcinogenesis. And also, GSK-3β was showed as a potential therapeutic target in various cancer involved in pancreatic, colon, renal, prostate, thyroid, ovarian cancer and leukemia [30-37].

Increasing evidence showed that DM was an independent risk factor for the prognosis of patients with HCC [15,38]. We focused on T2DM because type 1 and type 2 DM might have different impacts on HCC prognosis and their pathophysiology mechanisms were different. In this study, our findings showed that T2DM was associated with poor survival of patients with HCC. In the subgroup analysis, T2DM was a significant independent risk factor in early HCC (tumor size < or = 5 cm, P = 0.026 for recurrence, P = 0.028 for survival). While in the group of HCC with tumor size > 5 cm, T2DM showed no significant difference (P = 0.094 for recurrence, P = 0.125 for survival). The mechanism underlying the impact of DM on HCC prognosis was still unclear. Insulin resistance and hyperinsulinemia could result in increasing IGF-1. Both insulin and IGF-1 promoted proliferation and inhibited apoptosis by receptor-mediated pathways, which may lead to carcinogenesis [39].

This study focused on the impact of p-Ser9-GSK-3β on the prognosis of patients with HCC and the interaction among the expression levels of p-Ser9-GSK-3β, T2DM and the prognosis of HCC. Further studies are needed to confirm the interconnection or explain the complex mechanisms among them. We have begun a new study aimed at finding this potential mechanism by detecting the expression levels of other related molecules in multiple pathways involved in IGF, NF-κB, PI 3-kinase/Akt and Wnt/β-catenin pathways [40,41].

In conclusion, we firstly reported p-Ser9-GSK-3β was an independent prognostic factor of patients with HCC and it might mediate the influence of type 2 diabetes mellitus on the prognosis of patients with HCC.

**Supporting Information**

**Figure S1** Kaplan-Meier analysis of TTR and OS stratified by T2DM. (A,C) Kaplan-Meier curves of p-Ser9-GSK-3β expression level in the subgroup of without T2DM. (A) overall survival or (C) recurrence of HCC patients; (B,D) Kaplan-Meier curves of p-Ser9-GSK-3β expression level in the subgroup of with T2DM, (B) overall survival or (D) recurrence of HCC patients. (JPG)

**Table S1** Univariate analysis for overall survival. (DOCX)

**Author Contributions**

Conceived and designed the experiments: GQ FS. Performed the experiments: YL JL LW. Contributed reagents/materials/analysis tools: LW. Contributed to the writing of the manuscript: GQ FS. Performed the statistical analysis: GQ YL.
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Duffy JF, Hartt JR, Busuttil RW (2008) Surgical resection of hepatocellular carcinoma. Cancer J 14: 100–110.
3. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417–422.
4. Cagignan KM, Liu YJ (2006) Wnt signaling: complexity at the surface. J Cell Sci 119: 395–402.
5. Henriksen EJ, Dokken BB (2006) Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7: 1435–1441.
6. Lee J, Kim MS (2007) The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 77 Suppl 1: S49–57.
7. Zeng X, Huang H, Tani M, Zhang X, Harada Y, et al. (2008) Initiation of Wnt signaling: control of Wnt co-receptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135: 367–375.
8. Sutherland C, Leighton IA, Cohen P (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 (Pt 1): 15–19.
9. Luo J, Chen J, Deng ZL, Luo X, Song WX, et al. (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87: 97–103.
10. Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Beurel E, Boissan M, Deloé R, et al. (2002) Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 36: 1528–1536.
11. Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y, et al. (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167: 809–817.
12. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, et al. (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116: 1938–1946.
13. Poon RT, Fan ST, Wong J (2002) Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 97: 1480–1481.
14. Hao TI, Hsu CY, Huang HY, Hia CY, Lin HC, et al. (2010) Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 30: 198–207.
15. Shu WW, Shao YY, Yeh YC, Lin ZZ, Kuo R, et al. (2012) Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist 17: 856–862.
16. Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28: 109–122.
17. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–1236.
18. Wang K, Liu J, Yan ZL, Li J, Shi LH, et al. (2010) Overexpression of asparaginyl-(asparaginyl) beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 52: 164–173.
19. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462–503.
20. Ali A, Hoelfich KP, Woodgett JR (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101: 2327–2340.
21. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102.
22. Schuppin GT, Pons S, Hug S, Aciello LP, King GL, et al. (1998) A specific increased expression of insulin receptor substrate 2 in pancreatic beta-cell lines is involved in mediating serum-stimulated beta-cell growth. Diabetes 47: 1074–1085.
23. Sun XJ, Liu F (2009) Phosphorylation of IRS proteins Yin-Yang regulation of insulin signaling. Vitam Horm 80: 351–387.
24. White MF (2006) Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 84: 723–737.
25. Boche C, Serys S, Kuhn CR, Goldfine AB (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25: 807–830.
26. Patel S, Dohle B, Woodgett JR (2004) Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem Soc Trans 32: 803–808.
27. Bannasch P, Klimke F, Mayer D (1997) Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 29: 303–313.
28. Tanaka S, Sugimachi K, Maruhara S, Harimoto N, Shirabe K, et al. (2002) Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 131: S142–147.
29. Scharf JG, Braulke T (2003) The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35: 685–695.
30. Liao X, Zhang L, Thrasher JB, Du J, Li B (2003) Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2: 1215–1222.
31. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, et al. (2005) Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365–1373.
32. Cao Q, Lu X, Feng YJ (2006) Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16: 671–677.
33. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Snyrk TC, Charri ST, et al. (2002) aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 12: 5074–5081.
34. Kummimalayya M, Vaccaro AM, Nkaye MA, Chen H (2007) Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 6: 1151–1158.
35. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, et al. (2007) Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 98: 1388–1393.
36. Bilim V, Ougolkov A, Yudki K, Naito S, Kawaoze H, et al. (2009) Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 101: 2005–2014.
37. Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, et al. (2009) Potential therapeutic effect of glycogen synthase kinase-3beta inhibition against human glioblastoma. Clin Cancer Res 15: 887–897.
38. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54: 533–539.
39. Macaray VJ (1992) Insulin-like growth factors and cancer. Br J Cancer 65: 311–320.
40. Hoelfich KP, Luo J, Rubie EA, Tsao MS, Jin O, et al. (2006) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86–90.
41. Ban KC, Singh H, Krishnan R, Seove HF (2003) GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 199: 201–208.